Cebon J - Search Results

1

The Ludwig institute for cancer research Melbourne melanoma cell line panel.

Behren A, Anaka M, Lo PH, Vella LJ, Davis ID, Catimel J, Cardwell T, Gedye C, Hudson C, Stan R, Cebon J. Behren A, et al. Among authors: cebon j. Pigment Cell Melanoma Res. 2013 Jul;26(4):597-600. doi: 10.1111/pcmr.12097. Epub 2013 Apr 11. Pigment Cell Melanoma Res. 2013. PMID: 23527996 No abstract available.

2

Spontaneous T cell responses to melanoma differentiation antigens from melanoma patients and healthy subjects.

Chen Q, Jackson H, Gibbs P, Davis ID, Trapani J, Cebon J. Chen Q, et al. Among authors: cebon j. Cancer Immunol Immunother. 1998 Dec;47(4):191-7. doi: 10.1007/s002620050520. Cancer Immunol Immunother. 1998. PMID: 9875671 Free PMC article.

3

A direct comparison of cytolytic T-lymphocyte responses to Melan-A peptides in vitro: differential immunogenicity of Melan-A27-35 and Melan-A26-35.

Chen Q, Jackson H, Cebon J, Gibbs P, Davis ID, Trapani JA. Chen Q, et al. Among authors: cebon j. Melanoma Res. 2000 Feb;10(1):16-25. Melanoma Res. 2000. PMID: 10711636

4

A phase I and pharmacokinetic study of subcutaneously-administered recombinant human interleukin-4 (rhuIL-4) in patients with advanced cancer.

Davis ID, Maher DW, Cebon JS, Green MD, Fox RM, McKendrick JJ, Rybak ME, Boyd AW. Davis ID, et al. Among authors: cebon js. Growth Factors. 2000;17(4):287-300. doi: 10.3109/08977190009028972. Growth Factors. 2000. PMID: 10801077 Clinical Trial.

5

MAGE-12 and MAGE-6 are frequently expressed in malignant melanoma.

Gibbs P, Hutchins AM, Dorian KT, Vaughan HA, Davis ID, Silvapulle M, Cebon JS. Gibbs P, et al. Among authors: cebon js. Melanoma Res. 2000 Jun;10(3):259-64. Melanoma Res. 2000. PMID: 10890380

6

Exogenous peptides presented by transporter associated with antigen processing (TAP)-deficient and TAP-competent cells: intracellular loading and kinetics of presentation.

Luft T, Rizkalla M, Tai TY, Chen Q, MacFarlan RI, Davis ID, Maraskovsky E, Cebon J. Luft T, et al. Among authors: cebon j. J Immunol. 2001 Sep 1;167(5):2529-37. doi: 10.4049/jimmunol.167.5.2529. J Immunol. 2001. PMID: 11509592

7

The use of dendritic cells in cancer therapy.

Jefford M, Maraskovsky E, Cebon J, Davis ID. Jefford M, et al. Among authors: cebon j. Lancet Oncol. 2001 Jun;2(6):343-53. doi: 10.1016/s1470-2045(00)00389-2. Lancet Oncol. 2001. PMID: 11905751 Review.

8

Rational approaches to human cancer immunotherapy.

Davis ID, Jefford M, Parente P, Cebon J. Davis ID, et al. Among authors: cebon j. J Leukoc Biol. 2003 Jan;73(1):3-29. doi: 10.1189/jlb.0502261. J Leukoc Biol. 2003. PMID: 12525559 Review.

9

ATP gradients inhibit the migratory capacity of specific human dendritic cell types: implications for P2Y11 receptor signaling.

Schnurr M, Toy T, Stoitzner P, Cameron P, Shin A, Beecroft T, Davis ID, Cebon J, Maraskovsky E. Schnurr M, et al. Among authors: cebon j. Blood. 2003 Jul 15;102(2):613-20. doi: 10.1182/blood-2002-12-3745. Epub 2003 Mar 20. Blood. 2003. PMID: 12649135 Free article.

10

A phase I dose-escalation study of docetaxel with granulocyte colony-stimulating factor support in patients with solid tumours.

Mitchell PL, Basser R, Chipman M, Grigg A, Cebon J, Davis ID, Zalcberg J, Ng S, Appia F, Green M. Mitchell PL, et al. Among authors: cebon j. Ann Oncol. 2003 May;14(5):788-94. doi: 10.1093/annonc/mdg202. Ann Oncol. 2003. PMID: 12702535 Free article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

304 results

Search Page